AGN News and Press, Allergan plc From 05/23/19

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking John Paulson's Pau13lson & Company Portfolio ser...

James Brumley says in Kiplinger Investing : Rich people often get perpetually richer for a reason, so it could be worthwhile to study what billionaires and high-asset hedge funds are plowing their long-term capital into. Since any collection of stocks is more clearly understood when sub...

DUBLIN , May 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Commercial Officer William Meury will participate in a fireside chat at the Jefferies 2019 Healthcare Conference in New York, NY . The presentation will begin at 2:00 p.m. Eastern Time on Thursda...

According to Aerpio Pharmaceuticals (ARPO) website, they are a bio pharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Personally, I think the description is far too narrow and base my opinion on both the company's recent strong secondary readouts from ...

Market Assessment Allergan ( AGN ) is a commercial-stage large market cap ($45.9B) biopharma developing innovative and generic therapeutics for diseases affecting the eyes, bowel, lungs, skin, urogenital systems and brain. Through the acquisition of Tobira Therapeutics, Allergan has been...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...

DUBLIN , May 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the expansion of the PLEDGE program with a fifth study now evaluating relamorelin, an investigational, ghrelin agonist being studied for the treatment of diabetic gastroparesis (DG). Recruitment remains un...

Biotechnology stocks offer investors the potential to profit from the next generation of treatments. And because treatments are vast—covering everything from serious illness to cosmetic enhancements, investors are afforded a lot of choices. Because of this potential, this sector ...

BioVie Inc. ( BIVI ) should not have an enterprise value of $31 million. At that mark, the company is a sell. Other peers exhibiting a more advanced pipeline have a valuation close to that of BioVie Inc. Besides, the number of operating risks is elevated. The most worrying is that a significan...

Evolus ( EOLS ) is a one drug company that is gearing up to enter the personal aesthetics arena. They look to compete against the market leader, Allergan ( AGN ), with their own version of Botox, which will be branded as Jeuveau in the US. They have also recently received a positive opinion ...